<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762810</url>
  </required_header>
  <id_info>
    <org_study_id>Cyclophosphamide for IRPF</org_study_id>
    <nct_id>NCT04762810</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis</brief_title>
  <acronym>IRPF</acronym>
  <official_title>A Prospective Study to Evaluate the Efficacy and Safety of Cyclophosphamide in the Treatment of Idiopathic Retroperitoneal Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, interventional, controlled study is aimed to evaluate the efficacy and&#xD;
      safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which&#xD;
      refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue&#xD;
      that gradually evolves into fibroproliferative disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic retroperitoneal fibrosis is a chronic disease that requires treatment for a few&#xD;
      years. Patients with this disease respond well to glucocorticoid therapy, so you need to take&#xD;
      glucocorticoid medication once the diagnosis is established. In addition, most patients need&#xD;
      to use immunosuppressants when taking glucocorticoids. At present, the most commonly used&#xD;
      immunosuppressants in the world are cyclophosphamide, azathioprine, methotrexate and&#xD;
      mycophoranate, etc. The function of the above drugs is to improve the disorder of the immune&#xD;
      system function, in order to restore the normal immune state, so that the inflammation and&#xD;
      swelling of the affected organs disappear, restore the normal function. It should be&#xD;
      emphasized that if the use of hormones and immunosuppressant is not standard or stopped too&#xD;
      early, it can lead to disease recurrence. Therefore, after the disease is under control,&#xD;
      long-term adherence to medication is needed to maintain a stable state of the disease.&#xD;
&#xD;
      At present, there is no clear treatment guideline for idiopathic retroperitoneal fibrosis in&#xD;
      the world, and the addition of immunosuppressant is also out of debate. Therefore, a&#xD;
      comprehensive evaluation of its pathogenesis, clinical characteristics and treatment response&#xD;
      is needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission</measure>
    <time_frame>5 years</time_frame>
    <description>Patients achieve remission in symptoms and laboratory tets or radiologic images and have a low diseae activity after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Patients have a recurrence of symptoms or laboratory abnormalities and have a considerable diseae activity after achieving remission.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Patients have adverse events due to the drug treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Idiopathic Retroperitoneal Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide and Glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide and glucocorticoids</intervention_name>
    <description>Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.</description>
    <arm_group_label>Cyclophosphamide and Glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.</description>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-75 diagnosed as IRPF. The diagnosis of idiopathic retroperitoneal fibrosis is&#xD;
             based on the following aspects :(1) the swelling of retroperitoneal tissue , which&#xD;
             seems neoplastic; (2) A large number of lymphocytes proliferated and infiltrated in&#xD;
             the affected tissues and organs, and tissues showed inflammation, fibrosis and&#xD;
             sclerosis, in which IgG4-positive cells accounted for less than 50% of plasma cells;&#xD;
             (3) Increased inflammatory markers, such as ESR and CRP; (4) Good response to&#xD;
             glucocorticoid therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  malignancy retroperitoneal fibrosis secondary to other diseases or drugs or abdominal&#xD;
             surgeries.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunyun Fei</last_name>
      <phone>+8613681125226</phone>
      <email>feiyunyun2013@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wen Zhang</last_name>
      <email>zhangwen91@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Marzano A, Trapani A, Leone N, Actis GC, Rizzetto M. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis. 2001 Apr;60(4):427-8.</citation>
    <PMID>11247880</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006 Jan 21;367(9506):241-51. Review.</citation>
    <PMID>16427494</PMID>
  </reference>
  <reference>
    <citation>Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease? Trends Mol Med. 2008 Dec;14(12):522-9. doi: 10.1016/j.molmed.2008.09.008. Epub 2008 Nov 6. Review.</citation>
    <PMID>18980864</PMID>
  </reference>
  <reference>
    <citation>Qian Q, Kashani KB, Miller DV. Ruptured abdominal aortic aneurysm related to IgG4 periaortitis. N Engl J Med. 2009 Sep 10;361(11):1121-3. doi: 10.1056/NEJMc0905265.</citation>
    <PMID>19741239</PMID>
  </reference>
  <reference>
    <citation>Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011 Jan 4;154(1):31-6. doi: 10.7326/0003-4819-154-1-201101040-00005.</citation>
    <PMID>21200036</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011 Jul 23;378(9788):338-46. doi: 10.1016/S0140-6736(11)60934-3. Epub 2011 Jul 4.</citation>
    <PMID>21733570</PMID>
  </reference>
  <reference>
    <citation>Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, Walker UA, Peter HH, Warnatz K. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis. 2012 Feb;71(2):311-2. doi: 10.1136/annrheumdis-2011-200148. Epub 2011 Aug 22.</citation>
    <PMID>21859695</PMID>
  </reference>
  <reference>
    <citation>Alberici F, Palmisano A, Urban ML, Maritati F, Oliva E, Manenti L, Ferretti S, Cobelli R, Buzio C, Vaglio A. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013 Sep 1;72(9):1584-6. doi: 10.1136/annrheumdis-2013-203267. Epub 2013 May 21.</citation>
    <PMID>23696631</PMID>
  </reference>
  <reference>
    <citation>Fatima J, Gota C, Clair DG, Billings SD, Gornik HL. Inflammatory abdominal aortic aneurysm with retroperitoneal fibrosis. Circulation. 2014 Oct 7;130(15):1300-2. doi: 10.1161/CIRCULATIONAHA.114.010173.</citation>
    <PMID>25287771</PMID>
  </reference>
  <reference>
    <citation>Fernando A, Pattison J, Horsfield C, D'Cruz D, Cook G, O'Brien T. [(18)F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. Eur Urol. 2017 Jun;71(6):926-933. doi: 10.1016/j.eururo.2016.10.046. Epub 2016 Nov 18.</citation>
    <PMID>27876167</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Retroperitoneal Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

